Understanding the Link Between Fosamax and Osteonecrosis of the Jaw

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk

The legacy of general health and science information has long emphasized the importance of understanding how systemic factors influence tissue integrity and repair. In this broad context, the concept of drug exposure as a potential disruptor of normal physiological processes is well established. Transitioning from this general framework to a more specific concern, the focus narrows to the relationship between bisphosphonate therapy, such as Fosamax, and the risk of osteonecrosis of the jaw. This shift requires examining how chronic pharmacological intervention may alter bone metabolism and vascular supply in the maxillofacial region. The biological plausibility of such an association rests on the premise that potent inhibition of osteoclast activity, while beneficial for conditions like osteoporosis, could inadvertently impair the jawbone’s ability to remodel and repair itself, particularly after dental procedures or microtrauma. This concern is especially relevant in occupational settings where workers may have prolonged exposure to bisphosphonates, either through direct handling or environmental contamination, thereby elevating the risk of adverse outcomes. Thus, the transition from general health education to occupational exposure assessment underscores the need for targeted surveillance and preventive strategies in populations with sustained contact with these agents.

Biological Plausibility of Fosamax-Induced ONJ

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The biological plausibility of a causal link between Fosamax and ONJ is supported by mechanistic pathways, clinical evidence, and documented risk factors. The pharmacological action of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it can lead to adverse consequences in the jawbone. Multiscale characterization of jawbone treated with bisphosphonates, including alendronate, provides comprehensive information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using estrogen-deficient rat models has examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate therapy alters the normal remodeling dynamics of the jawbone, potentially predisposing it to necrosis when subjected to local stressors such as dental procedures or infection.

Clinical Evidence and Risk Factors

Clinical reports have established that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the medication, and a subset have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This indicates that while ONJ is a recognized adverse effect, its baseline incidence in clinical trial populations was low and not statistically distinguishable from placebo. Known risk factors for ONJ in patients taking bisphosphonates include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation Considerations and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the association, risk factors, and clinical course. The labeling also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects an awareness of cumulative risk. For causation-related considerations, the timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with the same or another bisphosphonate supports a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the presence of ONJ in placebo groups at similar rates in clinical trials complicates individual causation assessment, as does the fact that ONJ can occur spontaneously without bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanistic understanding from multiscale characterization of jawbone responses to bisphosphonates provides biological plausibility for a causal link, particularly in the context of local stressors such as dental procedures or infection (https://pubmed.ncbi.nlm.nih.gov/40345077). In summary, the evidence supports a biologically plausible association between Fosamax use and osteonecrosis of the jaw, mediated by bisphosphonate-induced suppression of bone turnover in the jawbone. Clinical data show variability in onset and resolution upon discontinuation, with recognized risk factors that include dental procedures and duration of therapy. Warnings in the prescribing information address these risks, though individual causation requires consideration of the specific clinical context.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological mechanism linking Fosamax to osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, reducing bone turnover. In the jawbone, this suppression of remodeling can impair healing after dental procedures or microtrauma, leading to necrosis. Multiscale characterization studies have shown altered tissue mineral density and mechanical stability in jawbone treated with bisphosphonates (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the prescribing information for Fosamax address ONJ?

The prescribing information includes a specific section on osteonecrosis of the jaw under warnings and precautions, describing the association, risk factors, and clinical course. It also recommends considering discontinuation after 3-5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.